Literature DB >> 32721475

MicroRNAs as regulators of VEGFA and NFE2L2 in cancer.

Caroline Izak Cuzziol1, Márcia Maria Urbanin Castanhole-Nunes1, Érika Cristina Pavarino1, Eny Maria Goloni-Bertollo2.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that are involved in post-transcriptional regulation of various genes, and their deregulation can lead to tumorigenesis. They may play the role of oncogenes or tumor suppressors by regulating different genes involved in cellular processes. One of the genes regulated by the miRNAs is the vascular endothelial growth factor A (VEGFA), which is responsible for angiogenesis. Angiogenesis is the process of formation of new blood vessels from pre-existing ones. This process plays an important role in tumor development, since it is responsible for the transport of nutrients required for tumor growth. Several studies have shown an increased expression of VEGFA in various cancers. Another gene regulated by miRNAs, the nuclear factor erythroid 2-like-2 (NFE2L2/NRF2), has a cytoprotective function and regulates cellular defense against oxidative stress. The NFE2L2 is the major regulator of cytoprotective agents and their oxidative damage to cells, which is down-regulated by Kelch-like ECH-associated protein 1 (KEAP1) at the post-transcriptional level. Regulation of the VEGFA and NFE2L2 by miRNAs has been observed in hepatocellular carcinoma and breast, lung, esophageal, endometrial, gastric, and ovarian cancer. This review highlights the role of miRNAs in the regulation of VEGFA and NFE2L2 and their relevance as therapeutic targets in various cancers.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; NFE2L2; Regulation; VEGFA; microRNAs

Mesh:

Substances:

Year:  2020        PMID: 32721475     DOI: 10.1016/j.gene.2020.144994

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer.

Authors:  Caroline Izak Cuzziol; Ludimila Leite Marzochi; Vitória Scavacini Possebon; Rosa Sayoko Kawasaki-Oyama; Marlon Fraga Mattos; Vilson Serafim Junior; Letícia Antunes Muniz Ferreira; Érika Cristina Pavarino; Márcia Maria Urbanin Castanhole-Nunes; Eny Maria Goloni-Bertollo
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 2.  Insights into the Role of Oxidative Stress in Ovarian Cancer.

Authors:  Dan-Ni Ding; Liang-Zhen Xie; Ying Shen; Jia Li; Ying Guo; Yang Fu; Fang-Yuan Liu; Feng-Juan Han
Journal:  Oxid Med Cell Longev       Date:  2021-10-07       Impact factor: 6.543

3.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

4.  A prognostic Risk Score model for oral squamous cell carcinoma constructed by 6 glycolysis-immune-related genes.

Authors:  Yi Liu; Tong Wang; Ronghua Li
Journal:  BMC Oral Health       Date:  2022-08-03       Impact factor: 3.747

5.  NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients.

Authors:  Corinna Preusse; Pascale Eede; Lucie Heinzeling; Kiara Freitag; Randi Koll; Waltraud Froehlich; Udo Schneider; Yves Allenbach; Olivier Benveniste; Anne Schänzer; Hans-Hilmar Goebel; Werner Stenzel; Josefine Radke
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.